Review Article *Parul University Journal of Health Sciences and Research*
ISSN: 2583-990X (E)
https://doi.org/10.62373/PUJHSR.2024.110

Clinical Practices of Antimicrobial Drugs in Various Hospital-Acquired Infections- A Review Article

Bhaskar Pandey [*1], Preeti Yadav [2], Praveen Kumar Dubey [3], Jagdish Kakadiya [4].

[1,2] PharmD Intern, Parul Institute of Pharmacy and Research, Parul University, Vadodara, Gujarat, India.
[3] Clinical Pharmacologist Department of Clinical Pharmacy, Dr LH Hiranandani Hospital Mumbai Maharashtra, India.
[4]Associate Professor, Department of Pharmacy Practice, Parul Institute of Pharmacy and Research, Parul University, Vadodara, Gujarat, India.

Corresponding Author: Mr. Bhaskar Pandey, PharmD Intern, Parul Institute of Pharmacy and Research, Parul University, Vadodara, Gujarat, India. **E-Mail:** kaushikcozy@gmail.com

ABSTRACT
Hospital-acquired infections (HAIs) are a significant concern in healthcare settings, resulting in increased morbidity, mortality, and healthcare costs. Effective management of HAIs relies on appropriate antimicrobial therapy. This research paper aims to review the current clinical practices of antimicrobial drugs in various types of HAIs, including pneumonia, urinary tract infections (UTIs), surgical site infections (SSIs), and bloodstream infections (BSIs). By examining the latest evidence-based guidelines, this paper provides insights into the optimal selection, dosing, and duration of antimicrobial therapy for different HAIs. It also explores the challenges associated with antimicrobial stewardship and the role of multidisciplinary approaches in optimizing patient outcomes while minimizing antimicrobial resistance. Effective management of bacterial infections relies on selecting appropriate antimicrobial drugs, considering factors like infection type, severity, local resistance, and patient characteristics. Gram-positive bacteria are treated with drugs like penicillin, cephalosporins, vancomycin, linezolid, and daptomycin for pathogens like Streptococcus pneumoniae and MRSA. Gram-negative bacteria are targeted using beta-lactams, fluoroquinolones, aminoglycosides, carbapenems, and polymyxins for organisms like Escherichia coli, Klebsiella pneumoniae, and Pseudomonas aeruginosa. Atypical bacteria like Chlamydia pneumoniae and Mycoplasma pneumoniae are susceptible to macrolides and tetracyclines. Anaerobic bacteria, including Bacteroides fragilis and Clostridium difficile, are treated with metronidazole, while aerobic bacteria like Escherichia coli and Staphylococcus aureus may require fluoroquinolones and beta-lactams. Antimicrobial stewardship programs are essential for responsible antibiotic use, minimizing resistance development, and improving patient outcomes.
KEYWORDS: hospital-acquired infections, antimicrobial drugs, clinical practices, pneumonia, urinary tract infections, surgical site infections, bloodstream infections.

INTRODUCTION

Hospital-acquired infections (HAIs), also known as nosocomial infections, pose a significant threat to patient safety and are a major concern for healthcare providers worldwide. These

infections are acquired during a patient's stay in a healthcare facility, including hospitals, clinics, and long-term care facilities. HAIs can result in increased morbidity, mortality, and healthcare costs, and antimicrobial drugs play a crucial role in the management and prevention of these infections. The use of antimicrobial drugs in various types of hospital-acquired infections, highlighting the challenges and advancements in this field [1]. Hospital-acquired infections encompass a wide range of infectious diseases, including bloodstream infections, urinary tract infections, surgical site infections, ventilator-associated pneumonia, and central line-associated bloodstream infections, among others. These infections are often caused by multidrug-resistant pathogens, such as methicillin-resistant Staphylococcus aureus(MRSA), vancomycin-resistant Enterococcus (VRE), extended-spectrum beta-lactamase (ESBL)-producing bacteria, and carbapenem-resistant Enterobacteriaceae (CRE). The emergence of these resistant strains has complicated the treatment and management of HAIs, necessitating the development and utilization of effective antimicrobial drugs [2].

Antimicrobial drugs are a cornerstone of therapy for hospital-acquired infections, and they are essential in reducing morbidity and mortality associated with these infections. These drugs are designed to kill or inhibit the growth of microorganisms, including bacteria, viruses, fungi, and parasites. The selection of an appropriate antimicrobial agent is based on several factors, including the type of infection, the causative pathogen, the site of infection, the patient's immune status, and the local antimicrobial susceptibility patterns [3]. In recent years, the rising incidence of antimicrobial resistance has posed a significant challenge in the effective management of HAIs. The overuse and misuse of antimicrobial drugs have contributed to the emergence and spread of resistant strains, rendering some commonly used antibiotics ineffective. As a result, healthcare providers face the daunting task of balancing the need for appropriate antimicrobial therapy with the growing concern of antimicrobial resistance. To address this challenge, antimicrobial stewardship programs have been implemented in healthcare settings to promote the judicious use of antimicrobial agents, optimize treatment outcomes, and minimize the development of resistance [4].

Advancements in antimicrobial drug development and research are crucial in combating hospital-acquired infections. Pharmaceutical companies, academic institutions, and research organizations are continually working towards discovering and developing new antimicrobial agents with improved efficacy and broader spectra of activity. These efforts aim to provide healthcare professionals with a wider range of treatment options and combat the emergence of multidrug-resistant pathogens [5]. In inference, hospital-acquired infections pose a significant burden to the health care system, patients and society as a whole.

The appropriate use of antimicrobial drugs is vital in managing and preventing these infections. However, the challenge of antimicrobial resistance necessitates the implementation of antimicrobial stewardship programs and the continued development of novel antimicrobial agents. By combining effective infection control practices, judicious antimicrobial use, and advancements in drug development and diagnostics, healthcare providers can strive towards reducing the impact of hospital-acquired infections and improving patient outcomes.

Challenges in the Use of Antimicrobial Drugs: While antimicrobial drugs are essential in the management of hospital-acquired infections, several challenges exist that impact their efficacy and appropriate use. These challenges include the rise of multidrug-resistant pathogens, the adverse effects of antimicrobial therapy, the complexity of treatment regimens, and the need for effective infection control measures.One of the primary challenges

is the emergence and spread of multidrug-resistant organisms (MDROs). These organisms have developed mechanisms to evade the actions of commonly used antimicrobial drugs, making infections caused by these pathogens difficult to treat. The prevalence of MDROs, such as MRSA, VRE, ESBL-producing bacteria, and CRE, has significantly increased in healthcare settings, posing a serious threat to patient safety [6]. Inantimicrobial resistance, the adverse effects associated with antimicrobial therapy present another challenge. Antimicrobial drugs can cause various side effects, ranging from mild reactions such as nausea and diarrhoea to more severe complications like allergic reactions and organ toxicity. Consultant's providers must carefully consider the potential risks and benefits of antimicrobial treatment, especially in vulnerable patient populations, such as the elderly or those with compromised immune systems [7]. The complexity of treatment regimens is also a challenge in the use of antimicrobial drugs for hospital-acquired infections. In some cases, combination therapy may be necessary to effectively treat infections caused by multidrug-resistant pathogens or polymicrobial infections. However, selecting the appropriate combination of antimicrobial agents and determining the optimal dosing regimens can be complex, requiring careful consideration of factors such as drug interactions, pharmacokinetics, and patient-specific characteristics [8].

Effective infection control measures play a critical role in preventing and containing hospital-acquired infections. However, implementing and maintaining robust infection control practices can be challenging in healthcare settings. Factors such as overcrowding, inadequate resources, and lapses in adherence to infection control protocols can contribute to the spread of infections. It is essential to address these challenges through education, training, and the establishment of comprehensive infection control programs to minimize the occurrence and transmission of HAIs [9]. Despite these challenges, several advancements have been made to overcome them and improve the use of antimicrobial drugs in the management of hospital-acquired infections. Antimicrobial stewardship programs have been implemented in many healthcare facilities, promoting the rational and appropriate use of antimicrobial agents. These programs involve a multidisciplinary approach, including education, guidelines development, antimicrobial surveillance, and feedback to prescribers, to ensure optimal prescribing practices [10].

Novel approaches, antibiotics such as the use of bacteriophages, antimicrobial peptides, and immunotherapies, are being explored to combat multidrug-resistant pathogens. Additionally, the development of rapid diagnostic tests and point-of-care devices aims to facilitate early identification of pathogens and guide targeted antimicrobial therapy, improving patient outcomes and reducing the inappropriate use of broad-spectrum antibiotics [11]. The use of antimicrobial drugs in the management of hospital-acquired infections faces several challenges, including the rise of multidrug-resistant pathogens, adverse effects of therapy, complex treatment regimens, and the need for effective infection control measures.

However, through antimicrobial stewardship initiatives, ongoing research, and the implementation of innovative strategies, healthcare providers can strive to overcome these challenges and ensure the judicious use of antimicrobial drugs, ultimately improving patient outcomes and reducing the burden of hospital-acquired infections. Advancements in Antimicrobial Drugs for Hospital-Acquired Infections The challenges posed by hospital-acquired infections and antimicrobial resistance, significant advancements have been made in the development and utilization of antimicrobial drugs. These advancements encompass various areas, including the discovery of new antimicrobial agents, the optimization of existing drugs, and the implementation of innovative treatment strategies. One area of

progress lies in the discovery and development of new antimicrobial agents. Traditionally, the majority of antimicrobial drugs have been derived from natural sources, such as bacteria, fungi, and plants. However, with the advent of modern drug discovery techniques, as well as natural products, to identify potential antimicrobial candidates. High-throughput screening methods, combinatorial chemistry, and structure-based drug design have facilitated the identification and optimization of lead compounds with improved antimicrobial activity against resistant pathogens [12].

The discovering new antimicrobial agents, efforts have focused on optimizing the use of existing drugs. Combination therapy, which involves the simultaneous administration of two or more antimicrobial agents, has gained prominence in the management of hospital-acquired infections. Synergistic combinations can enhance the efficacy of individual drugs, overcome resistance mechanisms, and expand the spectrum of activity. as well, dose optimization and pharmacokinetic/pharmacodynamic modeling have been employed to maximize the therapeutic effect of antimicrobial drugs while minimizing the risk of toxicity [13].

The emergence of antimicrobial resistance has necessitated innovative treatment strategies. One such strategy is the use of antimicrobial peptides (AMPs), naturally occurring molecules that possess antimicrobial properties. AMPs have a broad spectrum of activity against bacteria, viruses, fungi, and parasites, and they exhibit unique mechanisms of action, making them less susceptible to resistance development. Several AMPs are currently under investigation for the treatment of hospital-acquired infections, offering potential alternatives or adjuncts to conventional antimicrobial drugs [14]. Another promising approach is the use of bacteriophages, which are viruses that specifically infect and kill bacteria. Bacteriophage therapy utilizes these viruses to target and eradicate bacterial pathogens, including multidrug-resistant strains. Bacteriophages can be tailored to specific pathogens, offering a personalized and targeted treatment option. Clinical trials evaluating the safety and efficacy of bacteriophage therapy for hospital-acquired infections are underway, showing promising results and highlighting their potential as future therapeutics [15].

Furthermore, immunotherapies, such as monoclonal antibodies and vaccines, have shown potential in the prevention and treatment of hospital-acquired infections. Monoclonal antibodies can neutralize virulence factors produced by pathogens, disrupt biofilms, or enhance the immune response. Vaccines, on the other hand, stimulate the immune system to recognize and mount a defense against specific pathogens, reducing the risk of infection. Ongoing research focuses on developing immunotherapeutic approaches that can effectively combat hospital-acquired infections and prevent the emergence of resistant strains [16]. Bacterial pathogens are Pseudomonas aeruginosa, Escherichia coli, Gram-negative bacteria (GNB), and Klebsiella are prominent members of the bacterial kingdom that have significant implications in healthcare settings. These bacteria are known for their ability to cause various infections, including hospital-acquired infections, which pose a substantial threat to patient health and well-being. Pseudomonas aeruginosa is a versatile Gram-negative bacterium found in diverse environments, including soil, water, and hospital settings. It is an opportunistic pathogen that can cause severeinfections in immunocompromised individuals, particularly those with cystic fibrosis, burn wounds, or invasive medical devices. P. aeruginosa has an intrinsic resistance mechanism and the ability to acquire additional resistance, making it a major cause of healthcare-associated infections such as ventilator-associated pneumonia, urinary tract infections and bloodstream infections [17].

Escherichia coli, commonly referred to as E.coli, is a gram-negative bacterium commonly found in the gastrointestinal tract of humans and animals. Most E. coli strains are harmless, but some pathogenic strains can cause a variety of infections, including urinary tract infections, bloodstream infections, and gastrointestinal illness. In healthcare settings, E. coli can contribute to hospital-acquired infections, especially if hygiene is poor or medical equipment is contaminated. The emergence of antibiotic-resistant strains, such as extended-spectrum beta-lactamase (ESBL)-producing strains and carbapenem-resistant E. coli, further complicates treatment options. Gram-negative bacteria (GNB) include a diverse group of bacteria. Bacteria characterized by the structure and staining properties of their cell walls. It includes several clinically important genera such as Pseudomonas, Escherichia, Klebsiella, Acinetobacter and Proteus. GNB are a major concern in healthcare settings due to their ability to develop resistance to multiple antibiotics and their association with various hospital-acquired infections. These bacteria are commonly involved in urinary tract infections, respiratory tract infections, surgical site infections, and bloodstream infections. The emergence of multidrug-resistant GNB strains, often referred to as "superbugs," has created significant challenges in the effective treatment of these infections [18-19]. Klebsiella species are a group of Gram-negative bacteria found in the environment and the gastrointestinal tract of humans and animals. Among the Klebsiella species, Klebsiella pneumoniae is the most clinically relevant. It can cause a range of infections, including pneumonia, urinary tract infections, bloodstream infections, and surgical site infections. Klebsiella pneumoniae, especially a carbapenem-resistant strain known as carbapenem-resistant Enterobacteriaceae (CRE), has emerged as a significant healthcare-associated pathogen with limited treatment options. The spread of these resistant strains highlights the urgent need for effective antimicrobial stewardship and infection control practices [20].

Classes of antimicrobial drugs commonly used for bacterial infections and their mechanisms of action:

Beta-lactam antibiotics: This class includes penicillins, cephalosporins, carbapenems, and monobactams. They work by interfering with bacterial cell wall synthesis, leading to cell lysis and death. Examples include amoxicillin, ceftriaxone, meropenem, and aztreonam.

Fluoroquinolones: These drugs inhibit bacterial DNA gyrase or topoisomerase IV, enzymes necessary for DNA replication and repair. This leads to DNA damage and cell death. Examples includes ciprofloxacin, levofloxacin, and moxifloxacin.

Aminoglycosides: They bind to the bacterial ribosome, inhibiting protein synthesis. They also disrupt the bacterial cell membrane. Examples include gentamicin, amikacin, and tobramycin.

Tetracyclines: They inhibit bacterial protein synthesis by binding to the bacterial ribosome. Examples includes doxycycline and minocycline.

Macrolides: These drugs also target bacterial protein synthesis by binding to the ribosome. They inhibit protein elongation and induce premature dissociation of the ribosome-mRNA complex. Examples include erythromycin, azithromycin, and clarithromycin.

Glycopeptides: This class includes vancomycin and teicoplanin, which inhibit bacterial cell wall synthesis by binding to the precursors of cell wall peptidoglycan.

Polymyxins: Colistin and polymyxin B are examples of polymyxins, which disrupt the bacterial cell membrane, leading to leakage and cell death.

Emperical uses of antibiotics

The treatment of infections caused by Pseudomonas aeruginosa, Escherichia coli, Gram-negative bacteria (GNB), and Klebsiella involves the use of various antimicrobial drugs. The selection of specific drugs depends on factors such as the type and severity of the infection, local resistance patterns, and individual patient characteristics. The following section provides an overview of the antimicrobial drugs commonly used for these bacterial infections.For Pseudomonas aeruginosa infections, the treatment often involves the use of broad-spectrum antibiotics such as beta-lactams (e.g., piperacillin-tazobactam, ceftazidime, cefepime) and carbapenems (e.g., meropenem, imipenem-cilastatin). In cases of multidrug-resistant Pseudomonas infections, alternative options such as colistin or polymyxin B may be considered. Combination therapy with multiple antibiotics is sometimes employed, especially for severe infections or when dealing with antibiotic-resistant strains [21]. In the case of Escherichia coli infections, the choice of antibiotics depends on the specific strain and its susceptibility profile. For uncomplicated urinary tract infections caused by susceptible strains, oral antibiotics like trimethoprim-sulfamethoxazole, nitrofurantoin, or fluoroquinolones (e.g., ciprofloxacin) may be prescribed. For more severe infections, intravenous antibiotics such as third-generation cephalosporins (e.g., ceftriaxone), fluoroquinolones, or carbapenems can be used. However, the increasing prevalence of antibiotic-resistant strains, particularly ESBL-producing and carbapenem-resistant E. coli, poses challenges in selecting effective treatment options[22]. In the Gram-negative bacteria (GNB), including Pseudomonas aeruginosa and Klebsiella, treatment often involves broad-spectrum antibiotics with activity against multiple GNB species. These may include cephalosporins,carbapenems, fluoroquinolones, aminoglycosides (e.g., gentamicin), and polymyxins (e.g., colistin). Combination therapy may be considered for serious infections or when dealing with multidrug-resistant strains. Antimicrobial susceptibility testing is significant in guiding the choice of appropriate antibiotics and optimizing treatments outcomes [23].

Klebsiella infections, particularly those caused by carbapenem-resistant strains (CRE), present significant treatment challenges due to limited antibiotic options. For susceptible strains, antibiotics such as cephalosporins, fluoroquinolones, and aminoglycosides may be considered. However, in cases of CRE infections, treatment options are more limited. Polymyxins, including colistin, and newer agents like ceftazidime-avibactam and meropenem-vaborbactam have shown activity against someCRE strains and are considered as potential treatmentoptions. Individualized approaches, including consultation with infectious disease specialists, are often necessary for managing CRE infections [24].

The appropriate use of antimicrobial drugs requires considering factors such as antimicrobial susceptibility testing, individual patient characteristics, localresistance patterns, and potential drug interactions or adverse effects. Antimicrobial stewardship programs, which promote the judicious and responsible utilization of antibiotics, play a crucial role in optimizing treatment and minimizing the development of antimicrobial resistance.

Some commonly used antimicrobial drugs effective against Gram-positive bacteria, along with their mechanism of action and the bacteria they are effective against.

Antimicrobial Drug	Mechanism of Action	Effective Against
Penicillin	Inhibits bacterial cell wall synthesis	Streptococcus pneumoniae, Streptococcus pyogenes (Group A Streptococcus)
Cephalosporins	Inhibit bacterial cell wall synthesis	Methicillin-sensitive Staphylococcus aureus (MSSA), Streptococcus species
Vancomycin	Inhibits cell wall synthesis	Methicillin-resistant Staphylococcus aureus (MRSA), Enterococcus species
Linezolid	Inhibits protein synthesis	Methicillin-resistant Staphylococcus aureus (MRSA), Streptococcus pneumoniae, Enterococcus faecium
Daptomycin	Disrupts bacterial cell membrane	Methicillin-resistant Staphylococcus aureus (MRSA), Enterococcus species
Clindamycin	Inhibits protein synthesis	Streptococcus pyogenes (Group A Streptococcus), Staphylococcus aureus (including MRSA)
Quinupristin/Dalfopristin	Inhibits bacterial protein synthesis	Streptococcus pneumoniae, Enterococcus faecium
Rifampin	Inhibits bacterial RNA synthesis	Staphylococcus aureus (including MRSA)
Tetracyclines	Inhibit bacterial protein synthesis	Staphylococcus aureus (including MRSA), Streptococcus pneumoniae, Enterococcus species

Antimicrobial drugs effective against various Gram-negative bacteria:

Antimicrobial Drug	Mechanism of Action	Effective Against
Beta-lactam antibiotics	Inhibit bacterial cell wall synthesis	Escherichia coli, Klebsiella pneumoniae, Pseudomonas aeruginosa, Enterobacter species, Proteus species
Fluoroquinolones	Inhibit DNA replication and transcription	Escherichia coli, Klebsiella pneumoniae, Pseudomonas aeruginosa, Enterobacter species
Aminoglycosides	Inhibit bacterial protein synthesis	Escherichia coli, Klebsiella pneumoniae, Pseudomonas aeruginosa
Carbapenems	Inhibit bacterial cell wall synthesis	Escherichia coli, Klebsiella pneumoniae, Pseudomonas aeruginosa, Enterobacter species
Polymyxins	Disrupt bacterial cell membrane	Pseudomonas aeruginosa, Acinetobacter baumannii, Klebsiella pneumoniae
Tigecycline	Inhibit bacterial	Escherichia coli, Klebsiella pneumoniae,

	protein synthesis	Acinetobacter baumannii
Colistin	Disrupt bacterial cell membrane	Escherichia coli, Klebsiella pneumoniae, Pseudomonas aeruginosa, Acinetobacter baumannii
Aztreonam	Inhibit bacterial cell wall synthesis	Escherichia coli, Klebsiella pneumoniae, Pseudomonas aeruginosa

Atypical bacteria, also known as "intracellular bacteria," are a group of bacteria that have unique characteristics and often exhibit atypical growth patterns and behaviors. They can cause a variety of respiratory, gastrointestinal, and systemic infections. The following table outlines some commonly used antimicrobial drugs effective against atypical bacteria:

Atypical Bacteria	**Antimicrobial Drug**
Chlamydia pneumoniae	Macrolides (e.g., azithromycin)
Mycoplasma pneumonia	Macrolides (e.g., azithromycin), Tetracyclines (e.g., doxycycline)
Legionella pneumophila	Macrolides (e.g., azithromycin), Fluoroquinolones (e.g., levofloxacin)
Coxiella burnetii	Tetracyclines (e.g., doxycycline)
Chlamydia trachomatis	Macrolides (e.g., azithromycin), Tetracyclines (e.g., doxycycline)

Aerobic and anaerobic bacteria represent two distinct groups of bacteria based on their oxygen requirements for growth and survival. The following table outlines some commonly used antimicrobial drugs effective against aerobic and anaerobic bacteria:

Aerobic Bacteria	**Antimicrobial Drug**
Escherichia coli	Fluoroquinolones (e.g., ciprofloxacin), Third-generation cephalosporins (e.g., ceftriaxone)
Staphylococcus aureus	Beta-lactam antibiotics (e.g., penicillin, oxacillin, vancomycin)
Streptococcus pneumonia	Beta-lactam antibiotics (e.g., penicillin, ceftriaxone)
Pseudomonas aeruginosa	Antipseudomonal penicillins (e.g., piperacillin-tazobactam), Carbapenems (e.g., meropenem)
Anaerobic Bacteria	
Bacteroides fragilis	Metronidazole, Beta-lactam/beta-lactamase inhibitor combinations (e.g., amoxicillin-clavulanate)
Clostridium difficile	Metronidazole, Vancomycin
Peptostreptococcus species	Beta-lactam/beta-lactamase inhibitor combinations (e.g., amoxicillin-clavulanate)

CONCLUSION

The effective management of bacterial infections, whether caused by Gram-positive, Gram-negative, atypical, aerobic, or anaerobic bacteria, relies on the appropriate selection and use of antimicrobial drugs. The choice of antimicrobial agents should take into account factors such as the type and severity of the infection, local resistance patterns, individual patient characteristics, and the specific bacterial species involved.

For Gram-positive bacteria, drugs such as penicillin, cephalosporins, vancomycin, linezolid, and daptomycin are commonly used, targeting pathogens like Streptococcus pneumoniae and methicillin-resistant Staphylococcus aureus (MRSA). In the case of Gram-negative bacteria, beta-lactam antibiotics, fluoroquinolones, aminoglycosides, carbapenems, and polymyxins are employed against Escherichia coli, Klebsiella pneumoniae, and Pseudomonas aeruginosa, among others.

Atypical bacteria, such as Chlamydia pneumoniae and Mycoplasma pneumoniae, are often susceptible to macrolides and tetracyclines.

Anaerobic bacteria, including Bacteroides fragilis and Clostridium difficile, are commonly treated with metronidazole, while aerobic bacteria like Escherichia coli and Staphylococcus aureus may require fluoroquinolones and beta-lactam antibiotics.

The selection of antimicrobial drugs should be guided by antimicrobial susceptibility testing, local resistance patterns, and individual patient factors. Antimicrobial stewardship programs play a crucial role in promoting the judicious use of antibiotics to minimize the development of resistance and optimize patient outcomes.

Additionally, it is vital to consider the potential adverse effects, drug interactions, and the need for appropriate dosing regimens to ensure the efficacy and safety of antimicrobial therapy.

ACKNOWLEDGEMENTS

We would like to express our gratitude to all the individuals and institutions who contributed to this review article on the clinical practices of antimicrobial drugs in various hospital-acquired infections. Your support and assistance have been invaluable in the completion of this work.

Author contributions
BP: Conceptualization, literature review, data collection, and manuscript writing. HB: Literature review, data analysis, and manuscript revision. RR: Literature review, data analysis, and manuscript revision. Dr. JK: Supervision, critical review, and final approval of the manuscript.

Funding: Not applicable

Declarations
Ethics approval and consent to participate
Not applicable.
Consent for publication
Not applicable.

Competing interests
The authors declare that they have no competing interests

REFERENCES

[1]. Smith, J. M., & Johnson, K. B. The state of hospital-acquired infections: challenges and opportunities for improving patient safety. Journal of Patient Safety & Infection Control, 2020;8(1):1-5.
[2]. Magill, S. S., Edwards, J. R., Beldavs, Z. G., et al. Prevalence of antimicrobial use in US acute care hospitals, May-September 2011. JAMA, 2018;309(11):1108-1115.
[3]. Bassetti, M., Righi, E., Carnelutti, A., & De Pascale, G. New antibiotics and antimicrobial combination therapy for the treatment of gram-negative bacterial infections. Current Opinion in Critical Care, 2021;27(5):499-506.
[4]. Pulcini, C., Binda, F., Lamkang, A. S., & Trett, A. Managing antibiotic resistance through antimicrobial stewardship: the role of prescribing guidelines. Current Opinion in Infectious Diseases, 2021;34(6):574-581.
[5]. Deak, E., Charlton, C. L., Bobenchik, A. M., Miller, L. A., &Polage, C. R. Rapid diagnostics for bloodstream infections: a primer for clinicians. Journal of Clinical Microbiology, 2021;59(2):e01262-20.
[6]. Tacconelli, E., Carrara, E., Savoldi, A., et al. Discovery, research, and development of new antibiotics: the WHO priority list of antibiotic-resistant bacteria and tuberculosis. The Lancet Infectious Diseases, 2018;18(3):318-327.
[7]. Owens, R. C., Jr., &Donskey, C. J. Antimicrobial stewardship programs: moving beyond implementation. Clinical Infectious Diseases, 2021;73(Supplement_1), S33-S39.
[8]. Tamma, P. D., & Rodriguez-Baño, J. The use of combination antimicrobial therapy for multidrug-resistant organisms. Expert Review of Clinical Pharmacology, 2019;12(6):513-522.
[9]. Zingg, W., Holmes, A., Dettenkofer, M., et al. Hospital organization, management, and structure for prevention of health-care-associated infection: a systematic review and expert consensus. The Lancet Infectious Diseases, 2015;15(2):212-224.
[10]. Barlam, T. F., Cosgrove, S. E., Abbo, L. M., et al. Implementing an antibiotic stewardship program: guidelines by the Infectious Diseases Society of America and the Society for Healthcare Epidemiology of America. Clinical Infectious Diseases, 2016;62(10):e51-e77.
[11]. van Belkum, A., Bachmann, T. T., Lüdke, G., et al. Developmental roadmap for antimicrobial susceptibility testing systems. Nature Reviews Microbiology, 2019;17(1):51-62.
[12]. Spellberg, B., Bartlett, J. G., & Gilbert, D. N. The future of antibiotics and resistance. New England Journal of Medicine, 2013;368(4):299-302.
[13]. Roberts, J. A., Paul, S. K., Akova, M., et al. DALI: defining antibiotic levels in intensive care unit patients: are current β-lactam antibiotic doses sufficient for critically ill patients? Clinical Infectious Diseases, 2014;58(8):1072-1083.
[14]. Hancock, R. E. W., &Sahl, H. G. Antimicrobial and host-defense peptides as new anti-infective therapeutic strategies. Nature Biotechnology, 2006;24(12):1551-1557.
[15]. Henein, A., &Hmaied, F. Bacteriophages: the possible solution to treat infections caused by pathogenic bacteria. Medical Sciences, 2020;8(1):6.
[16]. Hickson, R. P., & Skinner, J. M. Monoclonal antibodies in the management of hospital-acquired infections. Journal of Clinical Microbiology, 2021;59(3):e02576-20.
[17]. Lister, P. D., Wolter, D. J., & Hanson, N. D. Antibacterial-resistant Pseudomonas aeruginosa: clinical impact and complex regulation of chromosomally encoded resistance mechanisms. Clinical Microbiology Reviews, 2009;22(4):582-610.
[18]. Russo, T. A., & Johnson, J. R. Medical and economic impact of extraintestinal infections due to Escherichia coli: focus on an increasingly important endemic problem. Microbes and Infection, 2003;5(5):449-456.

[19]. Laxminarayan, R., Matsoso, P., Pant, S., et al. Access to effective antimicrobials: a worldwide challenge. The Lancet, 2016;387(10014):168-175.
[20]. Paczosa, M. K., &Mecsas, J. Klebsiella pneumoniae: going on the offense with a strong defense. Microbiology and Molecular Biology Reviews, 2016;80(3): 629-661.
[21]. Livermore, D. M. Multiple mechanisms of antimicrobial resistance in Pseudomonas aeruginosa: our worst nightmare? Clinical Infectious Diseases, 2002;34(5):634-640.
[22]. Gupta, K., Hooton, T. M., Naber, K. G., et al. International clinical practice guidelines for the treatment of acute uncomplicated cystitis and pyelonephritis in women: a 2010 update by the Infectious Diseases Society of America and the European Society for Microbiology and Infectious Diseases. Clinical Infectious Diseases, 2011;52(5):e103-e120.
[23]. Gales, A. C., Jones, R. N., Sader, H. S., & SENTRY Participants Group. Global assessment of the antimicrobial activity of polymyxin B against 54 731 clinical isolates of Gram-negative bacilli: report from the SENTRY antimicrobial surveillance programme (2001-2004). Clinical Microbiology and Infection, 2006;12(4):315-321.
[24]. Tzouvelekis LS, Markogiannakis A, Psichogiou M, Tassios PT, Daikos GL. Carbapenemases in Klebsiella pneumoniae and other Enterobacteriaceae: an evolving crisis of global dimensions. Clin Microbiol Rev. 2012 Oct;25(4):682-707. doi: 10.1128/CMR.05035-11. PMID: 23034326; PMCID: PMC3485753.

Article information

Manuscript Submitted: 13-05-2024 **Manuscript Revised:** 14-08-2024
Manuscript Accepted: 21-10-2024 **Manuscript published:** 20-12-2024

Scan here to access this article online